Core Viewpoint - Corning Pharmaceutical-B (09966) experienced a significant stock price increase of 8.86%, reaching HKD 10.08, with a trading volume of HKD 18.195 million following the release of its interim results for the six months ending June 30, 2025 [1] Financial Performance - The company reported a revenue of RMB 319 million, representing an 84.05% year-on-year increase [1] - The net profit for the period was RMB 21.575 million, a turnaround from a loss of RMB 44.896 million in the same period last year, indicating a successful recovery [1] - Basic earnings per share were reported at RMB 0.02 [1] Research and Development Expenditure - R&D expenses increased from RMB 194.5 million for the six months ending June 30, 2024, to RMB 253.2 million for the current reporting period, an increase of RMB 58.7 million [1] - The rise in R&D spending is attributed to an increase in the number of ongoing clinical trials, expansion of clinical research scale, and progress in clinical trials for candidate drugs [1]
港股异动 | 康宁杰瑞制药-B(09966)盘中拉升逾8% 中期公司期内溢利2157.5万元 研发开支增加